Krystal Biotech, Inc.

Thank you for holding. We look forward to talking with you soon. Please hold the line and we'll be right back with you.

Thank you for standing by. and welcome to Crystal Biotech's first quarter 2024 earnings conference call. At this time, all participants are on a listen-only mode. After the speakers' presentations, there will be a question and answer session. During the question and answer session, there will be a limit of two questions per participant. As a reminder, today's conference is being recorded. I would now like to hand the conference over to your host, Stephan Paquette, Vice President of Corporate Development. Please begin.

Good morning, and thank you all for joining today's call. Earlier today, we released our financial results for the first quarter of 2024. The press release is available on our website at www.crystalbio.com. We also filed our earnings 8K, and thank you with the SEC earlier today. Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer, Suma Krishnan, President of Research and Development, Jennifer McDonough, Senior Vice President of Patient Access Analytics and Operations, Christine Wilson, Senior Vice President and Head of US Sales and Marketing, and Kate Romano, Chief Accounting Officer. This conference call will, and our responses to questions may, contain forward-looking statements. You are cautioned not to rely on these forward-looking statements, which are based on current expectations using the information available as of the date of this call, and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties, and other factors can be found in our SEC filings. With that, I will turn the call over to Krish.